Source-grounded facts extracted from CNBX Pharmaceuticals Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
CNBX Pharmaceuticals Inc. entered into Promissory Note with 3i L.P. valued at $45,000 (effective 2026-03-10).
“On March 10 th , 2026, the Company executed a non-convertible Promissory Note with 3i L.P., a Delaware Limited Partnership for the amount of $45,000.”
CNBX Pharmaceuticals Inc. engaged Elkana Amitai, CPA as its auditor.
“CNBX Pharmaceuticals Inc. (the “Company”) has replaced Weinstein International CPA (the “Former Accounting Firm”) as its independent registered public accounting firm, effective as of March 18 th , 2024, and has engaged Elkana Amitai, CPA, Rimon 1, Mitzpe Netofa, Israel (the “New Accounting Firm”) as its new independent registered public accounting firm as of and for the year ended August 31 st , 2023.”
Gil Feiler resigned as Director and Board Member at CNBX Pharmaceuticals Inc..
“Also on January 31 st , 2023, Gil Feiler also presented his resignation as a Director and Board Member.”
Dr. Inbar Maymon Pomeranchik resigned as Director and Board Member at CNBX Pharmaceuticals Inc..
“On January 31 st , 2023, Dr. Inbar Maymon Pomeranchik resigned from her position as a Director and Board Member.”
Shaul Yemal resigned as Director and Board Member at CNBX Pharmaceuticals Inc..
“On December 25th, 2022, Shaul Yemal resigned his position as Director and Board Member.”
Sanja Goldberg was appointed as Chief Technology Officer at CNBX Pharmaceuticals Inc..
“Dr. Sanja Goldberg was appointed as the Company’s new Chief Technology Officer on July 24 th , 2022.”
Eyal Ballan resigned as Chief Technology Officer at CNBX Pharmaceuticals Inc..
“Chief Technology Officer Dr. Eyal Ballan has resigned his position as CTO and his employment with the Company has ended effective July 20 th , 2022.”
Shaul Yemal was appointed as Independent Director at CNBX Pharmaceuticals Inc..
“On November 16 th , 2021, the Board of Directors (the “Board”) increased the size of the Board to five (5) members, and appointed Mr. Shaul Yemal to the Board as an Independent Director and as a member of the Audit Committee.”
Gabriel Yariv was appointed as Executive Chairman at CNBX Pharmaceuticals Inc..
“On September 5 rd , 2021, the Board of Directors nominated fellow Director Mr. Gabriel Yariv as Executive Chairman of the Board.”
Dr. Gil Feiler was appointed as Independent Board Member at CNBX Pharmaceuticals Inc..
“On July 15th, 2021, the Board of Directors appointed Dr. Gil Feiler as an Independent Board Member”
Inbar Maymon Pomeranchik was appointed as Independent Board Member at CNBX Pharmaceuticals Inc..
“On July 1 st , 2021, the Board of Directors appointed Dr. Inbar Maymon Pomeranchik as an Independent Board Member.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.